Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28236273 | 0.84 | VCAM1 (0.38) | — | |
| SCHEMBL21239456 | 0.80 | TRPA1 (0.35) | EPAS1GRM5 | |
| SCHEMBL30858740 | 0.80 | TRPA1 (0.35) | EPAS1GRM5 | |
| SCHEMBL28226221 | 0.77 | GABRG2 (0.42) | GRM5 | |
| SCHEMBL23027747 | 0.77 | CES2 (0.33) | — | |
| SCHEMBL1421650 | 0.77 | GRM5 (0.47) | GRM5 | |
| SCHEMBL11957883 | 0.77 | CES2 (0.39) | — | |
| SCHEMBL56741 | 0.77 | GRM5 (0.43) | GRM5 | |
| SCHEMBL19146345 | 0.76 | MIF (0.34) | GRM5 | |
| SCHEMBL28191360 | 0.75 | RXRA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795138-B2 | Process of fluorinating inorganic compounds by direct fluorination | Fujian Yongjing Technology Co.,Ltd (CN) | 2023-10-24 | — | — | US | disclosed |
| US-20220135516-A1 | Process of Fluorinating Inorganic Compounds by Direct Fluorination | Fujian Yongjing Technology Co.,Ltd (CN) | 2022-05-05 | — | — | US | disclosed |
| US-20210053911-A1 | Process of Fluorinating Inorganic or Organic Compounds by Direct Fluorination | FUJIAN YONGJING TECHNOLOGY CO., LTD (CN) | 2021-02-25 | — | — | US | disclosed |
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | CYTOKINETICS, INC. | 2012-07-05 | — | — | US | disclosed |
| US-8110595-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8101617-B2 | Disubstituted ureas and uses thereof in treating heart failure | AMGEN, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7989455-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090247544-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090192168-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2009-07-30 | — | — | US | disclosed |
| US-20090099198-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-7507735-B2 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090036447-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | TNNI3, TNNT2, MYLK2 | EPAS1 1003/4885GRM5 4415/4885 |
| US-11795138-B2 | Process of fluorinating inorganic compounds by direct fluorination | AFF2, CYP4F2, AFF1 | EPAS1 2851/4885GRM5 3411/4885 |
| US-20090099198-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | EPAS1 1671/4885GRM5 3495/4885 |
| US-20210053911-A1 | Process of Fluorinating Inorganic or Organic Compounds by Direct Fluorination | CYP4F2, AFF2, CYP4F3 | EPAS1 2883/4885GRM5 3818/4885 |
| US-20220135516-A1 | Process of Fluorinating Inorganic Compounds by Direct Fluorination | AFF2, CYP4F2, AFF1 | EPAS1 2851/4885GRM5 3411/4885 |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, MYLK2 | EPAS1 1256/4885GRM5 3718/4885 |
| US-20090036447-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | EPAS1 1671/4885GRM5 3495/4885 |
| US-20090247544-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | EPAS1 2477/4885GRM5 3138/4885 |
| US-20090192168-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | EPAS1 1867/4885GRM5 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.